Someone I love very much – in fact, a family member I idolize – was recently diagnosed with Parkinson’s disease. We are all in shock, and some members of my family are very frightened.
But I made a decision. Instead of being frightened, I’m going on the attack. As transformational thinking lecturer (and “Est” founder) Werner Hans Erhard advocates, I’m going to be “cause in the matter.”
So I’ve given myself a mission… to do my part to help find a cure.
And it’s an opportune time…
Major diseases like Parkinson’s, Alzheimer’s and diabetes have a new enemy: research initiatives that attack them from fantastic new angles – yielding new protocols and medicines that can stop these maladies in their tracks or even reverse their chilling effects.
I’m not talking about “old school” drug protocols or research. I’m referring to the new healthcare and research Disruptors that I’ve been watching – and that are everywhere.
A powerful confluence of catalysts is making this possible, including new science, new technologies and even new policies at the U.S. Food and Drug Administration (FDA) – such as a groundbreaking“Fast Track” designation that slashes the time it takes to get new drugs into the hands of the patients who need them.
My resolve to help fight Parkinson’s – as well as the other terrible diseases I mentioned – has already gained me access to some rarefied circles. I’ve been asked to join the board of an extraordinary company whose partnering doctors head up the research units in their respective medical specialties at the top hospitals in the United States.
I’m also helping raise money for research – which includes making contributions myself.
The doctors I’m backing are leaning into the future in a big way. The head of the research-and-development company I’m involved with previously ran a giant pharmaceutical company. He’s now attacking the diseases his old pharma company treated with drugs by developing completely new protocols to stop diseases from spreading and eventually reverse the damage that they do.
I’m not permitted to reveal the name of the company I’m working with just yet.
But I will make this promise: Over time – as we crusade toward our goals of arresting the spread of the diseases we’re attacking and advance development of reversal protocols – I will be able to share some of what we’re learning, how trials are going and how our success will benefit everyone.
Eventually, there may even be ways for you or your loved ones to get into trials (we’re not there yet, but getting closer) by participating directly through new healthcare Disruptor tools like iPads andiPhones.
Meanwhile, we can invest in the Disruptor players, a move that will have dual benefits. It will not only aid the eventual defeat of these dreaded diseases, but it will allow us to profit from the full-frontal assault on them.
And that’s what we’re going to start looking at today…
A True “Game-Changer”
As you probably gleaned from my reference to iPhones and iPads, Apple Inc. (Nasdaq: AAPL) is a focus of interest for me – a true Disruptor company whose muscle is changing an array of sectors, markets and disciplines.
The Cupertino, Calif.-based company and its stock obviously benefits from heavy analyst and media coverage – some might even say over-coverage.
Even so, because of the way I’m looking at this, you’re in for a beautiful awakening.
Tim Cook, Apple’s brilliant and visionary chief executive officer, recently appeared on Jim Cramer’sCNBCMad Money‘s 10th anniversary show, where he discussed the impact of the soon-to-shipApple Watch on medical research through the company’s ResearchKit open-source software framework. He told Cramer that the effect “has been so strong that, within the first 24 hours of announcing the ResearchKit, some 11,000 people signed up for a study in cardiovascular disease through Stanford University.”
In fact, Cook told Cramer “it would typically have taken 50 medical centers an entire year to sign up that many people.”
Here’s an example.
In a ResearchKit case study, Kathryn H. Schmitz, professor of epidemiology in biostatistics at theUniversity of Pennsylvania’s Perelman School of Medicine, recounted how they mailed printed fliers to 60,000 women and got only 305 to reply and sign up for a research project. She calls ResearchKit and Apple’s related HealthKit a “game-changer.”
And the disruptions don’t stop there.
Just on April 13, International Business Machines Corp. (NYSE: IBM) announced a far-reaching new partnership with Apple. IBM is linking its HIPAA-enabled Watson Health Cloud up with Apple’s HealthKit and ResearchKit. In conjunction with additional partners Johnson & Johnson (NYSE: JNJ) and Medtronic PLC (NYSE: MDT), IBM and Apple will develop“enterprise wellness apps” made possible by the merged medical and health data gleaned from Apple devices. Watson’s job will be to facilitate data-mining and provide predictive analytics.
The University of Rochester and Seattle nonprofit Sage Bionetworks are also working together to create the Parkinson’s research app, mPower, using Apple’s ResearchKit.
According to Sage, “mPower aims to make it easier for people to sign up for studies and providing consent to do so. The app can detect symptoms in Parkinson’s patients just by having them say ‘ahhhh’ into the phone. It also includes a finger-tapping feature that can detect symptoms, too. Finally, the app can analyze the user’s gait and balance by having them walk 20 steps then turn around and take 20 steps back.”
The Next Sector to Be Upended
As far as making money as you help with the assault on these terrible diseases, one way is owning Apple stock. Because of the “ecosystem” it is creating, Apple’s long-term financial health is, by design, tethered to the future health of the world.
That’s big, and it’s going to make Apple one of the world’s most critical companies. In turn, the company will become even more profitable and a fantastic long-term investment for decades to come.